Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics Q2 revenue rises 9.3% to $357.8 million; raises fiscal 2027 revenue guidance

Positive Impact 4 of 5 earnings

Haemonetics reported second-quarter fiscal 2027 revenue of $357.8 million, up 9.3%, and GAAP earnings of $1.00 per diluted share, up from $0.81 a year earlier. The company raised its reported revenue growth guidance to 8% to 11% but narrowed its adjusted operating margin expansion guidance to 0 to 50 basis points from 50 to 100 basis points.

Key points

  • Q2 revenue $357.8 million, up 9.3%; organic revenue growth 10.0%
  • GAAP EPS $1.00 vs. $0.81 a year earlier; adjusted EPS $1.35, up 6.3%
  • Reported revenue guidance raised to 8% to 11% from 5% to 8%; adjusted operating margin expansion lowered to 0 to 50 basis points from 50 to 100
  • Q2 operating cash flow $128.1 million; free cash flow $103.8 million

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:03 AM ET
Accession number0000313143-26-000150

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:18 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.